KAI Pharmaceuticals Announces Advancement Of KAI-4169 Clinical Program Into A ... - Medical News Today (press release) PDF Print
Medical News Today (press release)
Results obtained in the study will be used to select the appropriate dosing regimen for further development of KAI-4169 for the chronic management of SHPT in ESRD patients. Previous Phase 1 data demonstrated that single IV doses of KAI-4169 were safe

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.